logo-loader
viewImmuPharma PLC

Immupharma chairman details £2.66mln financing and open label extension study

ImmuPharma PLC’s (LON:IMM) chairman Tim McCarthy caught up with Proactive London's Andrew Scott to discuss the results of a follow-up study which was designed to evaluate Lupuzor’s safety and tolerability.

McCarthy says the six month extension study confirmed its outstanding and robust safety profile.

He also details the subscription agreement with institutional investor, Lanstead Capital, which brought in around £2.66mln.

Quick facts: ImmuPharma PLC

Price: 13.77 GBX

AIM:IMM
Market: AIM
Market Cap: £23.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' ...

The Life Sciences Division's Navid Malik gives his view on the recent recent deal ImmuPharma PLC (LON:IMM) struck with US speciality drugs group Avion Pharmaceuticals. Malik reckons its lupus candidate Lupuzor could become a 'US blockbuster' by generating over US$1bn revenues per year.

on 16/12/19

2 min read